Pregnancy after 35 is more common. Is U.S. health care keeping up?
This article was published in partnership with The 19th, a newsroom reporting on gender, politics and policy. Sara Toups thought […]
U.S
Ranking Member Cassidy Requests Information from Stakeholders on Improving Americans Access to Gene Therapies | The U.S. Senate Committee on Health, Education, Labor & Pensions
WASHINGTON Today, U.S. Senator Bill Cassidy, M.D. (R-LA), ranking member of the Senate Health, Education, Labor, and Pensions (HELP) Committee,
Uncategorized
Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the